Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 OragenicsQualigen TherapeuticsSELLAS Life Sciences GroupPLx PharmaEvoke Pharma
SymbolNYSEAMERICAN:OGENNASDAQ:QLGNNASDAQ:SLSNASDAQ:PLXPNASDAQ:EVOK
Price Information
Current Price$0.73$1.96$7.75$10.68$1.66
52 Week RangeHoldBuyN/ABuyBuy
MarketRank™
Overall Score0.61.30.51.51.4
Analysis Score0.00.00.03.33.5
Community Score2.65.02.52.13.0
Dividend Score0.00.00.00.00.0
Ownership Score0.00.80.01.70.0
Earnings & Valuation Score0.60.60.00.60.6
Analyst Ratings
Consensus RecommendationHoldBuyN/ABuyBuy
Consensus Price TargetN/AN/AN/A$16.00$10.00
% Upside from Price TargetN/AN/AN/A49.81% upside502.41% upside
Trade Information
Market Cap$80.04 million$45.20 million$116.91 million$232.69 million$53.74 million
Beta0.64-0.722.135.031.41
Average Volume20,961,5981,464,7221,617,166278,766725,795
Sales & Book Value
Annual RevenueN/AN/AN/A$570,000.00N/A
Price / SalesN/AN/AN/A408.22N/A
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$0.23 per share($1.13) per share$1.20 per share($1.32) per share$0.18 per share
Price / BookN/AN/AN/A-8.09N/A
Profitability
Net Income$-15,570,000.00$-1,670,000.00$-19,290,000.00$-20,500,000.00$-7,130,000.00
EPS($0.37)($26.50)N/A($4.74)($0.32)
Trailing P/E RatioN/AN/A0.00N/AN/A
Forward P/E RatioN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/AN/A-4,906.25%N/A
Return on Equity (ROE)-499.13%N/A-316.15%N/A-983.14%
Return on Assets (ROA)-178.75%-91.03%-122.78%-90.31%-188.91%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/AN/AN/AN/A
Current Ratio9.55%0.76%2.21%2.52%1.01%
Quick Ratio9.55%0.73%2.21%2.49%1.00%
Ownership Information
Institutional Ownership Percentage12.75%3.50%6.52%22.46%7.06%
Insider Ownership Percentage9.90%15.40%0.30%9.42%10.27%
Miscellaneous
Employees7347105
Shares Outstanding109.65 million23.06 million15.09 million21.79 million32.37 million
Next Earnings Date5/21/2021 (Estimated)5/7/2021 (Estimated)5/13/2021 (Estimated)5/21/2021 (Estimated)5/11/2021 (Estimated)
OptionableNot OptionableNot OptionableNot OptionableNot OptionableNot Optionable
SourceHeadline
Evoke Pharma, Inc. (NASDAQ:EVOK) Currently 267.46% Below Its 52-week High But The Upside Potential May Surprise YouEvoke Pharma, Inc. (NASDAQ:EVOK) Currently 267.46% Below Its 52-week High But The Upside Potential May Surprise You
marketingsentinel.com - April 18 at 7:00 AM
Short Interest in Evoke Pharma, Inc. (NASDAQ:EVOK) Grows By 46.7%Short Interest in Evoke Pharma, Inc. (NASDAQ:EVOK) Grows By 46.7%
americanbankingnews.com - April 17 at 1:01 PM
Analysts Expect Breakeven For Evoke Pharma, Inc. (NASDAQ:EVOK) Before LongAnalysts Expect Breakeven For Evoke Pharma, Inc. (NASDAQ:EVOK) Before Long
nasdaq.com - April 16 at 7:35 AM
Forced Into A Patient Advocate Role? Trust Your Business SkillsForced Into A Patient Advocate Role? Trust Your Business Skills
forbes.com - April 11 at 12:28 AM
CoronaVac? BBIBP-CorV? Sputnik? Meet the world’s three other COVID-19 vaccinesCoronaVac? BBIBP-CorV? Sputnik? Meet the world’s three other COVID-19 vaccines
thestar.com - April 11 at 12:28 AM
Evoke Pharma’s Gimoti nasal spray for treatment of gastroparesis receives US patentEvoke Pharma’s Gimoti nasal spray for treatment of gastroparesis receives US patent
pharmabiz.com - April 8 at 5:24 AM
Evoke Pharma Receives Notice of Allowance from United States Patent and Trademark Office for a ...Evoke Pharma Receives Notice of Allowance from United States Patent and Trademark Office for a ...
apnews.com - April 6 at 7:47 PM
Evoke Pharma Receives Notice of Allowance from United States Patent and Trademark Office for a Method of Use Patent with Claims Covering Gimoti®Evoke Pharma Receives Notice of Allowance from United States Patent and Trademark Office for a Method of Use Patent with Claims Covering Gimoti®
finance.yahoo.com - April 6 at 9:17 AM
Evoke Pharma Announces a Fireside Chat with Key Opinion Leaders on the Treatment of GastroparesisEvoke Pharma Announces a Fireside Chat with Key Opinion Leaders on the Treatment of Gastroparesis
finance.yahoo.com - March 30 at 12:38 PM
Wall Street’s take on Evoke Pharma, Inc. (NASDAQ:EVOK) stockWall Street’s take on Evoke Pharma, Inc. (NASDAQ:EVOK) stock
stocksregister.com - March 27 at 1:11 PM
Evoke Pharma, Inc. (NASDAQ:EVOK) Is Expected To Breakeven In The Near FutureEvoke Pharma, Inc. (NASDAQ:EVOK) Is Expected To Breakeven In The Near Future
finance.yahoo.com - March 14 at 2:08 PM
Evoke Pharma Reports Fourth Quarter and Full Year 2020 Financial ResultsEvoke Pharma Reports Fourth Quarter and Full Year 2020 Financial Results
finance.yahoo.com - March 11 at 7:50 PM
Evoke Pharma, Inc. (EVOK) Reports Q4 Loss, Misses Revenue EstimatesEvoke Pharma, Inc. (EVOK) Reports Q4 Loss, Misses Revenue Estimates
finance.yahoo.com - March 11 at 7:50 PM
Evoke Pharma, Inc. to Host Earnings CallEvoke Pharma, Inc. to Host Earnings Call
finance.yahoo.com - March 11 at 2:50 PM
Evoke Pharma to Report Fourth Quarter and Full Year 2020 Financial Results on March 11, 2021Evoke Pharma to Report Fourth Quarter and Full Year 2020 Financial Results on March 11, 2021
finance.yahoo.com - March 4 at 6:37 PM
Global Treatment for Gastroparesis Market 2020 Opportunity Assessment, Key Drivers and Challenges, Growth Rate and Forecast to 2025Global Treatment for Gastroparesis Market 2020 Opportunity Assessment, Key Drivers and Challenges, Growth Rate and Forecast to 2025
marketwatch.com - March 1 at 10:34 PM
The Escalator: Syneos Health Communications appoints six senior specialistsThe Escalator: Syneos Health Communications appoints six senior specialists
mmm-online.com - February 26 at 10:07 AM
Stock Alert: Evoke Pharma Gains 30%Stock Alert: Evoke Pharma Gains 30%
nasdaq.com - February 9 at 3:20 PM
Evoke Pharma Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional SharesEvoke Pharma Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriter's Option to Purchase Additional Shares
stockhouse.com - January 21 at 7:09 PM
Evoke Pharma Announces Closing of Public Offering of Common Stock and Full Exercise of ...Evoke Pharma Announces Closing of Public Offering of Common Stock and Full Exercise of ...
apnews.com - January 20 at 5:41 PM
Evoke Pharma Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriter’s Option to Purchase Additional SharesEvoke Pharma Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriter’s Option to Purchase Additional Shares
finance.yahoo.com - January 20 at 5:41 PM
EVOK Feb 2021 5.000 callEVOK Feb 2021 5.000 call
uk.finance.yahoo.com - January 17 at 9:27 PM
Evoke Pharma Announces Proposed Public Offering of Common StockEvoke Pharma Announces Proposed Public Offering of Common Stock
finance.yahoo.com - January 13 at 7:05 PM
Evoke Pharma Announces Positive Findings from GIMOTI Market Research StudyEvoke Pharma Announces Positive Findings from GIMOTI Market Research Study
wallstreet-online.de - January 13 at 2:04 PM
Evoke Pharma Announces Positive Findings from GIMOTI™ Market Research StudyEvoke Pharma Announces Positive Findings from GIMOTI™ Market Research Study
markets.businessinsider.com - January 13 at 9:04 AM
DateCompanyBrokerageAction
6/2/2020OragenicsHC WainwrightDowngrade
8/25/2020Qualigen TherapeuticsAlliance Global PartnersUpgrade
4/15/2021PLx PharmaOppenheimerInitiated Coverage
3/1/2021PLx PharmaJMP SecuritiesBoost Price Target
8/14/2020PLx PharmaRaymond JamesReiterated Rating
4/12/2019PLx PharmaJanney Montgomery ScottInitiated Coverage
3/4/2019Evoke PharmaB. RileySet Price Target
(Data available from 4/23/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.